TriSalus Life Sciences Announces Executive and Board Changes
Ticker: TLSIW · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1826667
| Field | Detail |
|---|---|
| Company | Trisalus Life Sciences, Inc. (TLSIW) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50, $50,000, $7,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-appointment, employment-agreement
TL;DR
TriSalus shakes up exec team & board, CEO gets new contract.
AI Summary
TriSalus Life Sciences, Inc. announced on January 29, 2025, a series of executive and board changes. Dr. Michael J. McGarrity has been appointed as Chief Medical Officer, and Dr. David M. Rind has joined the Board of Directors. Additionally, the company has entered into a new employment agreement with its Chief Executive Officer, Dr. Robert L. T. Ryan.
Why It Matters
These appointments and agreements signal a strategic shift or strengthening of leadership within TriSalus Life Sciences, potentially impacting its future direction and operational focus.
Risk Assessment
Risk Level: medium — Changes in key leadership and executive compensation can indicate internal shifts or challenges that may affect the company's stability and future performance.
Key Players & Entities
- TriSalus Life Sciences, Inc. (company) — Registrant
- Dr. Michael J. McGarrity (person) — Appointed Chief Medical Officer
- Dr. David M. Rind (person) — Appointed to Board of Directors
- Dr. Robert L. T. Ryan (person) — Chief Executive Officer
- January 29, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Michael J. McGarrity has been appointed as the Chief Medical Officer.
Who has joined the Board of Directors?
Dr. David M. Rind has joined the Board of Directors.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is January 29, 2025.
Has the CEO's employment agreement been updated?
Yes, the company has entered into a new employment agreement with its Chief Executive Officer, Dr. Robert L. T. Ryan.
What is the company's principal executive office address?
The principal executive offices are located at 6272 W 91st Ave, Westminster, Colorado 80031.
Filing Stats: 847 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-01-31 16:27:49
Key Financial Figures
- $0.0001 — ange on which registered Common stock, $0.0001 par value TLSI Nasdaq Global Market
- $11.50 — 's common stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Market
- $50,000 — will receive an annual cash retainer of $50,000 for service as a member of the Board, a
- $7,500 — e an additional annual cash retainer of $7,500 for his service as a member of the Audi
Filing Documents
- tlsi-20250129.htm (8-K) — 28KB
- 0001826667-25-000011.txt ( ) — 192KB
- tlsi-20250129.xsd (EX-101.SCH) — 2KB
- tlsi-20250129_def.xml (EX-101.DEF) — 16KB
- tlsi-20250129_lab.xml (EX-101.LAB) — 27KB
- tlsi-20250129_pre.xml (EX-101.PRE) — 16KB
- tlsi-20250129_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 31, 2025 TriSalus Life Sciences, Inc. By: /s/ James Young Name: James Young Title: Chief Financial Officer